|
Quantitative densitometry of SNCA in situ hybridization |
|||||
| SNCA densitometry R/L ratio |
|||||
|
|
|||||
| Brain region |
PBS (N = 9) |
Luciferase siRNA (N = 10) |
SNCA siRNA (N = 11) |
P-value: SNCA vs. Luciferase |
P-value: SNCA vs. PBS |
|
|
|||||
| Cortex |
0.92 (0.82 – 0.98) |
0.90 (0.86 – 1.00) |
0.27 (0.20 – 0.90) |
0.036 |
0.067 |
| CA1 |
1.02 (0.98 – 1.14) |
0.97 (0.93 – 1.06) |
0.35 (0.14 – 0.54) |
<0.001 |
<0.001 |
| CA2 |
1.02 (0.93 – 1.05) |
1.01 (0.97 – 1.15) |
0.42 (0.19 – 0.62) |
<0.001 |
<0.001 |
| CA3 |
1.15 (0.99 – 1.24) |
1.09 (1.01 – 1.15) |
0.27 (0.12 – 0.71) |
<0.001 |
<0.001 |
| DG |
1.02 (0.99 – 1.11) |
0.99 (0.94 – 1.04) |
0.19 (0.10 – 0.68) |
0.008 |
0.001 |
|
Using densitometry to determine efficacy of SNCA siRNA, SNCA expression in the injected (PBS, luciferase siRNA or SNCA siRNA) right side was compared to the uninjected left side and compared across treatment groups. P-values were derived from Wilcoxon rank sum test and the sample median (25th percentile – 75th percentile) is given. | |||||
Lewis et al. Molecular Neurodegeneration 2008 3:19 doi:10.1186/1750-1326-3-19 |
|||||